WS19.03 Improvements in structural lung disease over 24 months in children with CF aged 6-11 on elexacaftor/tezacaftor/ivacaftor (ETI) – interim analysis using automated LungQ scoring
P. McNally, K. Lester, Rachel Cregan, P. Makani et autres
ie, nl, gb (code pays fourni par la source)